203 related articles for article (PubMed ID: 33714975)
1. Hepatic sinusoidal obstruction syndrome and short-term application of 6-thioguanine in pediatric acute lymphoblastic leukemia.
Stanulla M; Schaeffeler E; Möricke A; Buchmann S; Zimmermann M; Igel S; Schmiegelow K; Flotho C; Hartmann H; Illsinger S; Sauerbrey A; Junk SV; Schütte P; Hinze L; Lauten M; Modlich S; Kolb R; Rossig C; Schwabe G; Gnekow AK; Fleischhack G; Schlegel PG; Schünemann HJ; Kratz CP; Cario G; Schrappe M; Schwab M
Leukemia; 2021 Sep; 35(9):2650-2657. PubMed ID: 33714975
[TBL] [Abstract][Full Text] [Related]
2. TPMT and MTHFR genotype is not associated with altered risk of thioguanine-related sinusoidal obstruction syndrome in pediatric acute lymphoblastic leukemia: a report from the Children's Oncology Group.
Wray L; Vujkovic M; McWilliams T; Cannon S; Devidas M; Stork L; Aplenc R
Pediatr Blood Cancer; 2014 Nov; 61(11):2086-8. PubMed ID: 24737678
[TBL] [Abstract][Full Text] [Related]
3. The thiopurine methyltransferase genetic polymorphism is associated with thioguanine-related veno-occlusive disease of the liver in children with acute lymphoblastic leukemia.
Lennard L; Richards S; Cartwright CS; Mitchell C; Lilleyman JS; Vora A;
Clin Pharmacol Ther; 2006 Oct; 80(4):375-83. PubMed ID: 17015055
[TBL] [Abstract][Full Text] [Related]
4. Treatment-related sinusoidal obstruction syndrome in children with de novo acute lymphoblastic leukemia during intensification.
McAtee CL; Schneller N; Brackett J; Bernhardt MB; Schafer ES
Cancer Chemother Pharmacol; 2017 Dec; 80(6):1261-1264. PubMed ID: 29051993
[TBL] [Abstract][Full Text] [Related]
5. Understanding thiopurine methyltransferase polymorphisms for the targeted treatment of hematologic malignancies.
Franca R; Braidotti S; Stocco G; Decorti G
Expert Opin Drug Metab Toxicol; 2021 Oct; 17(10):1187-1198. PubMed ID: 34452592
[TBL] [Abstract][Full Text] [Related]
6. Substitution of oral and intravenous thioguanine for mercaptopurine in a treatment regimen for children with standard risk acute lymphoblastic leukemia: a collaborative Children's Oncology Group/National Cancer Institute pilot trial (CCG-1942).
Jacobs SS; Stork LC; Bostrom BC; Hutchinson R; Holcenberg J; Reaman GH; Erdmann G; Franklin J; Neglia JP; Steinberg SM; Balis FM; Adamson PC; ;
Pediatr Blood Cancer; 2007 Sep; 49(3):250-5. PubMed ID: 16856155
[TBL] [Abstract][Full Text] [Related]
7. DNA-TG and risk of sinusoidal obstruction syndrome in childhood acute lymphoblastic leukemia.
Toksvang LN; Grell K; Nielsen SN; Nersting J; Murdy D; Moorman AV; Vora A; Schmiegelow K
Leukemia; 2022 Feb; 36(2):555-557. PubMed ID: 34535761
[No Abstract] [Full Text] [Related]
8. Hepatic sinusoidal obstruction syndrome during maintenance therapy of childhood acute lymphoblastic leukemia is associated with continuous asparaginase therapy and mercaptopurine metabolites.
Toksvang LN; De Pietri S; Nielsen SN; Nersting J; Albertsen BK; Wehner PS; Rosthøj S; Lähteenmäki PM; Nilsson D; Nystad TA; Grell K; Frandsen TL; Schmiegelow K
Pediatr Blood Cancer; 2017 Sep; 64(9):. PubMed ID: 28423235
[TBL] [Abstract][Full Text] [Related]
9. Thiopurine methyltransferase genotype-phenotype discordance and thiopurine active metabolite formation in childhood acute lymphoblastic leukaemia.
Lennard L; Cartwright CS; Wade R; Richards SM; Vora A
Br J Clin Pharmacol; 2013 Jul; 76(1):125-36. PubMed ID: 23252716
[TBL] [Abstract][Full Text] [Related]
10. Thiopurine methyltransferase activity is related to the risk of relapse of childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study.
Schmiegelow K; Forestier E; Kristinsson J; Söderhäll S; Vettenranta K; Weinshilboum R; Wesenberg F;
Leukemia; 2009 Mar; 23(3):557-64. PubMed ID: 18987654
[TBL] [Abstract][Full Text] [Related]
11. Thiopurine dose intensity and treatment outcome in childhood lymphoblastic leukaemia: the influence of thiopurine methyltransferase pharmacogenetics.
Lennard L; Cartwright CS; Wade R; Vora A
Br J Haematol; 2015 Apr; 169(2):228-40. PubMed ID: 25441457
[TBL] [Abstract][Full Text] [Related]
12. Thiopurine methyltransferase (TPMT) genotype and early treatment response to mercaptopurine in childhood acute lymphoblastic leukemia.
Stanulla M; Schaeffeler E; Flohr T; Cario G; Schrauder A; Zimmermann M; Welte K; Ludwig WD; Bartram CR; Zanger UM; Eichelbaum M; Schrappe M; Schwab M
JAMA; 2005 Mar; 293(12):1485-9. PubMed ID: 15784872
[TBL] [Abstract][Full Text] [Related]
13. Oral 6-mercaptopurine versus oral 6-thioguanine and veno-occlusive disease in children with standard-risk acute lymphoblastic leukemia: report of the Children's Oncology Group CCG-1952 clinical trial.
Stork LC; Matloub Y; Broxson E; La M; Yanofsky R; Sather H; Hutchinson R; Heerema NA; Sorrell AD; Masterson M; Bleyer A; Gaynon PS
Blood; 2010 Apr; 115(14):2740-8. PubMed ID: 20124218
[TBL] [Abstract][Full Text] [Related]
14. Two Cases of Veno-occlusive Disease/Sinusoidal Obstruction Syndrome After Thioguanine Treatment for Acute Lymphoblastic Leukemia.
Gruhn B; Brodt G; Mentzel HJ; Ernst J
J Pediatr Hematol Oncol; 2022 Mar; 44(2):e572-e575. PubMed ID: 33885036
[TBL] [Abstract][Full Text] [Related]
15. Possible implication of thiopurine S-methyltransferase in occurrence of infectious episodes during maintenance therapy for childhood lymphoblastic leukemia with mercaptopurine.
Dervieux T; Médard Y; Verpillat P; Guigonis V; Duval M; Lescoeur B; Suciu S; Vilmer E; Jacqz-Aigrain E
Leukemia; 2001 Nov; 15(11):1706-12. PubMed ID: 11681411
[TBL] [Abstract][Full Text] [Related]
16. No association between relapse hazard and thiopurine methyltransferase geno- or phenotypes in non-high risk acute lymphoblastic leukemia: a NOPHO ALL2008 sub-study.
Nielsen SN; Toksvang LN; Grell K; Nersting J; Abrahamsson J; Lund B; Kanerva J; Jónsson ÓG; Vaitkeviciene G; Pruunsild K; Appell ML; Hjalgrim LL; Schmiegelow K
Cancer Chemother Pharmacol; 2021 Aug; 88(2):271-279. PubMed ID: 33928426
[TBL] [Abstract][Full Text] [Related]
17. Sinusoidal Obstruction Syndrome of the Liver Associated With 6-Mercaptopurine During Maintenance in a Child With T-cell Acute Lymphoblastic Leukemia.
Prudowsky ZD; Schafer ES; Brackett J; Herbison AB; Shapiro MC
J Pediatr Hematol Oncol; 2023 Jan; 45(1):e121-e123. PubMed ID: 36036518
[TBL] [Abstract][Full Text] [Related]
18. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus.
Relling MV; Hancock ML; Rivera GK; Sandlund JT; Ribeiro RC; Krynetski EY; Pui CH; Evans WE
J Natl Cancer Inst; 1999 Dec; 91(23):2001-8. PubMed ID: 10580024
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of 6-Thioguanine and 6-Mercaptopurine Combination Maintenance Therapy of Childhood ALL: Hypothesis and Case Report.
Nielsen SN; Frandsen TL; Nersting J; Hjalgrim LL; Schmiegelow K
J Pediatr Hematol Oncol; 2015 Apr; 37(3):e206-9. PubMed ID: 25171455
[TBL] [Abstract][Full Text] [Related]
20. Veno-occlusive disease in patients receiving thiopurines during maintenance therapy for childhood acute lymphoblastic leukaemia.
Stoneham S; Lennard L; Coen P; Lilleyman J; Saha V
Br J Haematol; 2003 Oct; 123(1):100-2. PubMed ID: 14510948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
